Chicago Becomes U.S. Base for Global Rare Disease Company

Chicago Becomes U.S. Base for Global Rare Disease Company

by John Conrad| Sep 9, 2024| NewsBrief

Immedica Pharma AB, a Stockholm-based pharmaceutical company specializing in rare and severe diseases, has announced its expansion into the United States market. The company has established Immedica Pharma US Inc., with headquarters in Chicago, marking a significant milestone in its global growth strategy.

This expansion builds upon Immedica's strong presence in Europe and the Middle East, positioning the company to become a global leader in the rare disease sector. The new U.S. entity will focus on introducing innovative therapies to the American market, enhancing treatment options for patients with rare diseases.

Anders Edvell, CEO of Immedica Pharma, emphasized the importance of this move: "This expansion into the U.S. is a pivotal moment for Immedica as we continue our mission to deliver life-changing therapies to people living with rare diseases. Our presence in the U.S will allow us to better serve the needs of patients in North America and marks a pivotal step in Immedica's ongoing commitment to serving unmet medical needs on a global scale."

John Conrad, President and CEO of iBIO (Illinois Biotechnology Innovation Organization), welcomed Immedica's decision to establish its U.S. operations in Chicago: "Immedica's choice to base their U.S. commercial business in Chicago is a testament to the growing strength of our life sciences ecosystem here in Illinois. Our community has developed significant expertise in rare disease drug development and commercialization, making it an ideal location for companies like Immedica. This move not only reinforces our position as a hub for innovation in the life sciences but also promises to bring new treatments to patients with rare diseases across the country."

Founded in 2018, Immedica has quickly grown to employ over 120 people across Europe, the Middle East, and now the United States. The company's expertise spans various crucial areas, including marketing and sales, compliance, pharmacovigilance, and medical affairs. Immedica's global distribution network currently serves patients in more than 50 countries.

With this expansion, Immedica reinforces its dedication to addressing unmet medical needs in genetic and metabolic diseases, hematology, oncology, and specialty care. The establishment of a U.S. presence is expected to accelerate the company's growth and enhance its ability to serve patients worldwide, while also contributing to the thriving life sciences sector in the Chicago area.

Read the Press Release